Patiromer Powder for Oral Suspension (Part A)

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Hyperkalemia

Drug Information

Target Indication

Hyperkalemia

Clinical Trial

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Regulatory Approvals

EMA7/19/2017

Veltassa

Veltassa is indicated for the treatment of hyperkalaemia in adults and adolescents aged 12 to 17 years.

Drug Science

Mechanism of action & safety profile

Developer

FMS

Fresenius Medical Care AG

Related Pipeline

General Anesthesia

Nutrition Therapy

Parenteral Nutrition

Chronic Kidney Failure

Postmenopausal Osteoporosis

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts